Author:
Wu Xiaofang,Zhao Lei,Zhang Yujiang,Li Kailong,Yang Jurong
Abstract
Diabetic kidney disease (DKD) is a common complication in patients with diabetes mellitus (DM). Increasing evidence suggested that the gut microbiota participates in the progression of DKD, which is involved in insulin resistance, renin-angiotensin system (RAS) activation, oxidative stress, inflammation and immunity. Gut microbiota-targeted therapies including dietary fiber, supplementation with probiotics or prebiotics, fecal microbiota transplantation and diabetic agents that modulate the gut microbiota, such as metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose transporter-2 (SGLT-2) inhibitors. In this review, we summarize the most important findings about the role of the gut microbiota in the pathogenesis of DKD and the application of gut microbiota-targeted therapies.
Subject
Physiology (medical),Physiology
Reference146 articles.
1. Kidney function improvement by soy milk containing Lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: A double-blinded randomized controlled trial;Abbasi;Iran. J. Kidney Dis.,2017
2. GLP-1 and GLP-2 orchestrate intestine integrity, gut microbiota, and immune system crosstalk;Abdalqadir;Microorganisms,2022
3. Histological manifestations of diabetic kidney disease and its relationship with insulin resistance;Adeva-Andany;Curr. Diabetes Rev.,2022
4. Role of oxidative stress and inflammatory factors in diabetic kidney disease;Aghadavod;Iran. J. Kidney Dis.,2016
5. Diabetic kidney disease: Past and present;Akhtar;Adv. Anat. Pathol.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献